Jihui Chen1, Zhipeng Wang2, Shouhong Gao2, Kejin Wu3, Fang Bai3, Qiqiang Zhang1, Hongyu Wang1, Qin Ye1, Fengjing Xu2, Hong Sun4, Yunshu Lu5, Yan Liu6. 1. Department of Pharmacy, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai, 200092, China. 2. Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China. 3. Department of Breast Surgery, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China. 4. Department of Pharmacy, Provincial Clinical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, 350001, China. 5. Department of Breast Surgery, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China. Luyunshu@xinhuamed.com.cn. 6. Department of Pharmacy, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai, 200092, China. liuyan03@xinhuamed.com.cn.
Abstract
AIM: Pemetrexed, a new generation antifolate drug, has been approved for the treatment of locally advanced or metastatic breast cancer. However, factors affecting its efficacy and resistance have not been fully elucidated yet. ATP-binding cassette (ABC) transporters are predictors of prognosis as well as of adverse effects of several xenobiotics. This study was designed to explore whether ABC transporters affect pemetrexed resistance and can contribute to the optimization of breast cancer treatment regimen. METHODS: First, we measured the expression levels of ABC transporter family members in cell lines. Subsequently, we assessed the potential role of ABC transporters in conferring resistance to pemetrexed in primary breast cancer cells isolated from 34 breast cancer patients and the role of ABCC5 in mediating pemetrexed transport and apoptotic pathways in MCF-7 cells. Finally, the influence of ABCC5 expression on the therapeutic effect of pemetrexed was evaluated in an in vivo xenograft mouse model of breast cancer. RESULTS: The expression levels of ABCC2, ABCC4, ABCC5, and ABCG2 significantly increased in the pan-resistant cell line, and the ABCC5 level in the MCF-7-ADR cell line was 5.21 times higher than that in the control group. ABCC5 expression was inversely correlated with pemetrexed sensitivity (IC50, r = 0.741; p < 0.001) in breast cancer cells derived from 34 patients. Furthermore, we found that the expression level of ABCC5 influenced the efflux and cytotoxicity of pemetrexed in MCF-7 cells, with IC50 values of 0.06 and 0.20 μg/mL in ABCC5 knockout and over-expression cells, respectively. In the in vivo study, we observed that ABCC5 affected the sensitivity of pemetrexed in breast tumor-bearing mice, and the tumor volume was much larger in the ABCC5-overexpressing group than in the control group when compared with their own initial volumes (2.7-fold vs. 1.3-fold). CONCLUSIONS: Our results indicated that ABCC5 expression was associated with pemetrexed resistance in vitro and in vivo, and it may serve as a target or biomarker for the optimization of pemetrexed regimen in breast cancer treatment.
AIM: Pemetrexed, a new generation antifolate drug, has been approved for the treatment of locally advanced or metastatic breast cancer. However, factors affecting its efficacy and resistance have not been fully elucidated yet. ATP-binding cassette (ABC) transporters are predictors of prognosis as well as of adverse effects of several xenobiotics. This study was designed to explore whether ABC transporters affect pemetrexed resistance and can contribute to the optimization of breast cancer treatment regimen. METHODS: First, we measured the expression levels of ABC transporter family members in cell lines. Subsequently, we assessed the potential role of ABC transporters in conferring resistance to pemetrexed in primary breast cancer cells isolated from 34 breast cancer patients and the role of ABCC5 in mediating pemetrexed transport and apoptotic pathways in MCF-7 cells. Finally, the influence of ABCC5 expression on the therapeutic effect of pemetrexed was evaluated in an in vivo xenograft mouse model of breast cancer. RESULTS: The expression levels of ABCC2, ABCC4, ABCC5, and ABCG2 significantly increased in the pan-resistant cell line, and the ABCC5 level in the MCF-7-ADR cell line was 5.21 times higher than that in the control group. ABCC5 expression was inversely correlated with pemetrexed sensitivity (IC50, r = 0.741; p < 0.001) in breast cancer cells derived from 34 patients. Furthermore, we found that the expression level of ABCC5 influenced the efflux and cytotoxicity of pemetrexed in MCF-7 cells, with IC50 values of 0.06 and 0.20 μg/mL in ABCC5 knockout and over-expression cells, respectively. In the in vivo study, we observed that ABCC5 affected the sensitivity of pemetrexed in breast tumor-bearing mice, and the tumor volume was much larger in the ABCC5-overexpressing group than in the control group when compared with their own initial volumes (2.7-fold vs. 1.3-fold). CONCLUSIONS: Our results indicated that ABCC5 expression was associated with pemetrexed resistance in vitro and in vivo, and it may serve as a target or biomarker for the optimization of pemetrexed regimen in breast cancer treatment.
Entities:
Keywords:
ABC transporter; Breast cancer; Drug resistance; Pemetrexed; Sensitivity
Authors: Nicholas J Robert; Paul R Conkling; Mark A O'Rourke; Paul R Kuefler; Kristi J McIntyre; Feng Zhan; Lina Asmar; Yanping Wang; Oluwatoyin O Shonukan; Joyce A O'Shaughnessy Journal: Breast Cancer Res Treat Date: 2010-12-25 Impact factor: 4.872
Authors: Csilla Hegedüs; Ágnes Telbisz; Tamás Hegedűs; Balázs Sarkadi; Csilla Özvegy-Laczka Journal: Adv Cancer Res Date: 2015-01-08 Impact factor: 6.242
Authors: Chengcheng Liu; Laura J Janke; Jun J Yang; William E Evans; John D Schuetz; Mary V Relling Journal: Cancer Chemother Pharmacol Date: 2017-06-16 Impact factor: 3.333
Authors: Ji Hyun Park; Byoung Soo Kwon; So Jung Park; Wonjun Ji; Shinkyo Yoon; Chang-Min Choi; Jae Cheol Lee Journal: J Cancer Res Clin Oncol Date: 2019-05-29 Impact factor: 4.553
Authors: Matvey M Tsyganov; Marina K Ibragimova; Kseniya A Gaptulbarova; Irina A Tsydenova; Daria S Dolgasheva; Evgeniy Y Garbukov; Anastasia A Frolova; Elena M Slonimskaya; Nikolai V Litvyakov Journal: Pharmaceutics Date: 2022-04-27 Impact factor: 6.525